Genetic analysis of tumor samples from the randomized clinical trial PALOMA-3 (fulvestrant treatment with palbociclib or placebo) showed that higher levels of the CCNE1 gene (encoding for cyclin E1) correlated with relative resistance to palbociclib [88]. The gene discussed is CCNE1; the disease is neoplasm.